Abstract
Background: Atrial fibrillation (AF) is one of the most common causes of hospital admission, with a prevalence of up to 5% of the population, increasing with advancing age. Emergency direct current cardioversion is the therapy of choice when arrhythmia leads to hemodynamic compromise, but in patients who are hemodynamically stable, antiarrhythmic drugs are usually given to restore sinus rhythm.
Hypothesis: The study was undertaken to assess the efficacy of intravenous amiodarone in cardioversion of recent‐onset paroxysmal atrial fibrillation (AF). No standard antiarrhythmic therapy has been accepted for pharmacologic cardioversion of AF. Amiodarone seems to be a promising candidate, but only few randomized trials are available and the results are inconsistent.
Methods: In all, 160 patients with AF lasting < 24 h were randomly assigned (2:1 fashion) to the amiodarone group (n = 106) receiving 5 mg/kg as a 30 min intravenous (IV) infusion, followed by IV infusion of 10 mg/kg during 20 h diluted in 1000 ml of 10% glucose with 20 IU of rapid‐action insulin, 80 mEq of potassium chloride, and 8 g of magnesium sulphate (GIKM), or to the control group (n = 54) receiving 1000 ml of GIKM alone. Treatment was continued up to 20 h independent of sinus rhythm restoration.
Results: Sinus rhythm was restored 20 h after initiation of therapy in 88 (83%) patients in the amiodarone group and in 24 (44%) patients in the control group (p < 0.0001). The difference between efficacy of the two treatment modalities became significant already after 8 h of therapy (53 vs. 14 patients with sinus rhythm, respectively, p < 0.05). The mean dose of amio‐darone administered until sinus rhythm restoration was 740 ± 296 mg. The presence and the type of underlying heart disease did not influence the conversion rate in either group. In two patients (1.8%) treated with amiodarone, the return of sinus rhythm was preceded by asystole.
Conclusion: Amiodarone is effective in the termination of AF lasting < 24 h. It may be particularly useful in patients with organic heart disease in whom class I antiarrhythmic agents may be contraindicated. During treatment, the heart rhythm should be monitored continuously.
Keywords: amiodarone, recent‐onset atrial fibrillation, pharmacologic cardioversion
Full Text
The Full Text of this article is available as a PDF (45.5 KB).
References
- 1. Bialy D, Lehman MH, Schumacher DN: Hospitalization for arrhythmia in the United States. Importance of atrial fibrillation. J Am Coll Cardiol 1992; 19(suppl. A): 41A [Google Scholar]
- 2. Kannel W, Abbott RD, Savage DD, McNamara P: Epidemiologic features of atrial fibrillation: The Framingham Study. N Engl J Med 1982; 306:1018–1022 [DOI] [PubMed] [Google Scholar]
- 3. Pritchett E: Management of atrial fibrillation. N Engl J Med 1992; 326:1264–1271 [DOI] [PubMed] [Google Scholar]
- 4. Ganz LI, Antman EM: Antiarrhythmic drug therapy in the management of atrial fibrillation. J Cardiovasc Electrophysiol 1997; 8:1175–1189 [DOI] [PubMed] [Google Scholar]
- 5. Masoudi FA, Goldschlager N: The medical management of atrial fibrillation. Cardiol Clin 1997; 15:689–719 [DOI] [PubMed] [Google Scholar]
- 6. Donovan KD, Power BM, Hockings BEF, Dobb GJ, Lee K‐Y: Intravenous flecainide versus amiodarone for recent‐onset atrial fibrillation. Am J Cardiol 1995; 75:693–697 [DOI] [PubMed] [Google Scholar]
- 7. Kochiadakis GE, Igoumenidis NE, Simantirakis EN, Marketou ME, Parthenakis FI, Mezilis NE, Vardas PE: Intravenous proAFenone versus intravenous amiodarone in management of atrial fibrillation of recent onset: A placebo‐controlled study. PACE 1998; 21:2475–2479 [DOI] [PubMed] [Google Scholar]
- 8. Cotter G, Blatt A, Kaluski E, Metzkor‐Cotter M, Koren M, Litinski I, Simantov R, Moshkovitz Y, Zaidenstein R, Peleg E, Vered Z, Golik A: Conversion of recent‐onset paroxysmal atrial fibrillation to normal sinus rhythm: The effect of no treatment and high‐dose amiodarone. A randomised, placebo‐controlled study. Eur Heart J 1999; 20:1833–1842 [DOI] [PubMed] [Google Scholar]
- 9. Martinez‐Marcos FJ, Garcia‐Garmendia JL, Ortega‐Carpio A, Fernandez‐Gomez JM, Santos JM, Camacho C: Comparison of intravenous flecainide, proAFenone and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86:950–953 [DOI] [PubMed] [Google Scholar]
- 10. Dell'Orfano JT, Patel H, Wolbrette D, Luck JC, Nacarelli CV: Acute treatment of atrial fibrillation: Spontaneous conversion rates and cost of care. Am J Cardiol 1999; 83:788–790 [DOI] [PubMed] [Google Scholar]
- 11. Negrini M, Gibelli G, De Ponti C: A comparison of proAFenone and amio‐darone in reversion of recent‐onset atrial fibrillation to sinus rhythm. Curr Therapeut Res 1994; 55:1345–1354 [Google Scholar]
- 12. Hou Z‐Y, Chang C‐Y, Chen M‐S, Tu MS, Lin SL, Chiang HT, Woosley RL: Acute treatment of recent‐onset atrial fibrillation and flutter with tailored dosing regimen of intravenous amiodarone. A randomised, digoxin‐controlled study. Eur Heart J 1995; 16:521–528 [DOI] [PubMed] [Google Scholar]
- 13. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, Garcia‐Dorado D, Soler‐Soler J: Intravenous amiodarone in treatment of recent‐onset atrial fibrillation: Results of a randomised, controlled study. J Am Coll Cardiol 1996; 27:1079–1082 [DOI] [PubMed] [Google Scholar]
- 14. Boriani G, Biffi M, Capucci A, Botto G, Ongari M, Trisolino G, Rubino I, Sanguinetti M, Branzi A, Mangani B: Conversion of recent‐onset atrial fibrillation to sinus rhythm: Effects of different drug protocols. PACE 1998; 21:2470–2474 [DOI] [PubMed] [Google Scholar]
- 15. Peuhkurinen K, Niemela M, Ylitalo A, Linnaluoto M, Lilja M, Juvonen J: Effectiveness of amiodarone as single oral dose for recent onset atrial fibrillation. Am J Cardiol 2000; 85:462–465 [DOI] [PubMed] [Google Scholar]
- 16. Joseph AP, Ward MR: A prospective, randomized, controlled trial comparing the efficacy and safety of sotalol, amiodarone and digoxin for the reversion of new‐onset atrial fibrillation. Ann Emerg Med 2001; 36:1–9 [DOI] [PubMed] [Google Scholar]
- 17. Hohnloser SH, Meinertz T, Demmbacher T, Steiert K, Jahnchen E, Zehender M, Fraedrich G, Just H: Electrocardiographic and antiarrhythmic effects of intravenous amiodarone. Results of prospective placebo‐controlled study. Am Heart J 1991; 121:89–95 [DOI] [PubMed] [Google Scholar]
- 18. Kulakowski P, Karczmarewicz S, Karpinski G, Soszynska M, Ceremuzynski L: Effects of intravenous amiodarone on ventricular refractoriness, intra‐ventricular conduction and ventricular tachycardia induction. Europace 2000; 2:207–215 [DOI] [PubMed] [Google Scholar]
- 19. Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, Della Casa S, Sanguinetti M, Magnani B: Oral proAFenone to convert recent‐onset atrial fibrillation in patients with and without underlying heart disease. Ann Intern Med 1997; 126:621–625 [DOI] [PubMed] [Google Scholar]